Short answer
Nuvation Bio Inc. (NUVB) filed its Q1 2026 10-Q quarterly report on May 4, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $83M (up 2598.7% year over year) with net income of $5M.
Q1 2026 key financials · XBRL
- Revenue
- $83M
- +2598.7% YoY
- Net income
- $5M
- +110.1% YoY
- Operating margin
- 4.7%
- EPS (diluted)
- $0.01
- +106.3% YoY
Source: XBRL data from the Nuvation Bio Inc. (NUVB) Q1 2026 10-Q on SEC EDGAR. USD.
Nuvation Bio Inc. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $83.2M, up from $3.1M YoY, including $18.5M IBTROZI product revenue
- Collaboration revenue $64.7M, up $61.6M YoY, driven by $58.7M Eisai upfront license payment
- Net income $5.4M versus $53.2M net loss YoY
- Cash $533.7M; operating cash flow $5.1M versus $42.6M used YoY
- Outlook: cash expected to fund operations through at least next 12 months; substantial future development funding required
Risk Factors
- New commercialization risk triggered by June 2025 FDA approval and U.S. launch of IBTROZI as the company’s only marketed product
- Commercial execution risk from limited U.S. launch experience and potentially mis-sized sales and medical-support teams
- Regulatory compliance risk from post-marketing requirements for U.S. and China approvals, with noncompliance potentially causing penalties or withdrawal
- Market risk from competitors offering safer, more effective, less costly, or more convenient ROS1+ NSCLC treatments
- Financial risk from substantial funding needs and debt-service obligations before IBTROZI generates sufficient revenue
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Nuvation Bio Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.